Evicenter
P&T meetings

SL1009 (sodium dichloroacetate)

Pyruvate dehydrogenase complex deficiency

Manufacturer
Saol Therapeutics
Regulatory submission
NDA resubmitted June 2026
Launch
Not announced
Last updated
78 sources

Clinical evidence

Partial pyruvate decarboxylase deficiency treated with dichloroacetate and benzoate

7 evidence topics · 2 sources

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using serum lactate and pyruvate as the biochemical outcomes

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

Not applicable.

Results
Participant disposition

No evidence found.

Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

The biochemical reductions were reported in one participant. They do not establish a comparative clinical benefit, long-term neurologic effect, or survival effect. No systematic adverse-event results are included in the retrieved evidence.